Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Rethinking the diagnostic criteria of polycythemia vera

Leukemia volume 28, pages 1191–1195 (2014)Cite this article

Subjects

Abstract

The aim of this review is to critically address the validity and clinical applicability of three major diagnostic classification systems for polycythemia vera (PV), that is, those proposed by the Polycythemia Vera Study Group (PVSG), the British Committee for Standards in Haematology (BCSH) and the World Health Organization (WHO). Special focus is on which one of the three red cell parameters (hemoglobin—HB, hematocrit—HCT and red cell mass—RCM) should be used as the diagnostic hallmark of PV. The revised BCSH employed a persistently raised HCT level as the first diagnostic criterion in combination with the presence of a JAK2V617F mutation. On the other hand, the WHO classification used a raised HB value as a surrogate for increased RCM in association with molecular markers and for the first time, the bone marrow (BM) morphology was included as a minor criterion. Ongoing controversy and discussion regards the use of certain threshold values for HCT and HB as surrogates for RCM as well as the existence of prodromal-latent disease, so-called masked PV (mPV). It has been shown that mPV can be recognized in patients not meeting the required HB or HCT threshold levels by both the WHO and BCSH criteria. These cases present with the same baseline clinical features as overt PV but present worsened survival. A critical reappraisal of the WHO criteria may suggest either to reduce the thresholds for HB or to consider HCT values as major diagnostic criterion, as in the BCSH, in association with JAK2V617F mutation. The clinical utility of using HCT as reference variable is supported also by results of clinical trials which explicitly recommend to use the HCT threshold for monitoring treatment. In questionable cases as in mPV, BM biopsy examinations should be mandated together with mutation analysis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD . Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI (eds). Polycythemia Vera and the Myeloproliferative Disorders. W.B. Saunders: Philadelphia, 1995; pp 166–194.

    Google Scholar 

  2. McMullin MF, Reilly JT, Campbell P, Bareford D, Green AR, Harrison CN et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 2007; 138: 821–822.

    Article  PubMed  Google Scholar 

  3. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097.

    Article  CAS  PubMed  Google Scholar 

  4. Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Birgegard G . Polycythaemia vera. In: Swerdlow S, Campo E, Harris N, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008; pp 40–43.

    Google Scholar 

  5. Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–2466.

    Article  CAS  PubMed  Google Scholar 

  6. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

    Article  CAS  PubMed  Google Scholar 

  7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  PubMed  Google Scholar 

  8. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

    Article  CAS  PubMed  Google Scholar 

  9. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  PubMed  Google Scholar 

  10. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A . Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F negative polycythemia vera. Leukemia 2007; 21: 1960–1963.

    Article  CAS  PubMed  Google Scholar 

  11. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Spivak JL . Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272–4290.

    Article  CAS  PubMed  Google Scholar 

  13. Johansson PL, Safai-Kutti S, Kutti J . An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 2005; 129: 701–705.

    Article  CAS  PubMed  Google Scholar 

  14. Spivak JL, Silver RT . The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008; 112: 231–239.

    Article  CAS  PubMed  Google Scholar 

  15. Tefferi A . The rise and the fall of red cell mass measurement in polycythemia vera. Curr Hematol Malign Rep 2005; 4: 213–217.

    Google Scholar 

  16. Alvarez-Larrán A, Ancochea A, Angona A, Pedro C, García-Pallarols F, Martínez-Avilés L et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 2012; 97: 1704–1707.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ . Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013; 122: 1881–1886.

    Article  CAS  PubMed  Google Scholar 

  18. Thiele J, Kvasnicka HM, Zankovich R, Diehl V . The value of bone marrow histology indifferentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001; 86: 368–374.

    CAS  PubMed  Google Scholar 

  19. Thiele J, Kvasnicka HM, Diehl V . Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005; 113: 213–219.

    Article  PubMed  Google Scholar 

  20. Gianelli U, Iurlo A, Vener C, Moro A, Fermo E, Bianchi P et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008; 30: 336–342.

    Article  Google Scholar 

  21. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol 2013; e-pub ahead of print 31 August 2013; doi:10.1002/ajh.23585.

    Article  PubMed  Google Scholar 

  22. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31: 737–740.

    Article  PubMed  Google Scholar 

  23. Ellis JT, Peterson P, Geller SA, Rappaport H . Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986; 23: 144–155.

    CAS  PubMed  Google Scholar 

  24. Berlin NI . Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339–351.

    CAS  PubMed  Google Scholar 

  25. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR . Therapeutic recommendations in polycythemia vera based on PVSG protocols. Semin Hematol 1986; 23: 132–143.

    CAS  PubMed  Google Scholar 

  26. Murphy S . Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36: 9–13.

    CAS  PubMed  Google Scholar 

  27. Pearson TC . Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol 1998; 11: 695–720.

    Article  CAS  PubMed  Google Scholar 

  28. Pearson TC . Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001; 38: 21–24.

    Article  CAS  PubMed  Google Scholar 

  29. Messinezy M, Pearson TC . The classification and diagnostic criteria of the erythrocytoses (polycythaemias). Clin Lab Haem 1999; 21: 309–316.

    Article  CAS  Google Scholar 

  30. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130: 174–195.

    Article  PubMed  Google Scholar 

  31. Pearson TC . Apparent polycythaemia. Blood Rev 1991; 5: 205–213.

    Article  CAS  PubMed  Google Scholar 

  32. Tefferi A . The rise and the fall of red cell mass measurement in polycythemia vera. Curr Hematol Rep 2005; 4: 213–217.

    PubMed  Google Scholar 

  33. Sirhan S, Fairbanks VF, Tefferi A . Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. Cancer 2005; 104: 213–215.

    Article  PubMed  Google Scholar 

  34. Ellis JT, Silver RT, Coleman M, Geller SA . The bone marrow in polycythemia vera. Semin Hematol 1975; 12: 433–444.

    CAS  PubMed  Google Scholar 

  35. Ellis JT, Peterson P . The bone marrow in polycythemia vera. Pathol Ann 1979; 1: 383–403.

    Google Scholar 

  36. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27: 1874–1881.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Thiele J, Kvasnicka HM . Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005; 20: 47.

    Google Scholar 

  38. Thiele J, Schneider G, Hoeppner B, Wienhold S, Zankovich R, Fischer R . Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis—features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch 1988; (A) 413: 407–417.

    Article  CAS  Google Scholar 

  39. Buhr T, Georgii A, Schuppan O, Amor A, Kaloutsi V . Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. Ann Hematol 1992; 64: 286–291.

    Article  CAS  PubMed  Google Scholar 

  40. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H . Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996; 22 (Suppl 1): 15–29.

    Article  PubMed  Google Scholar 

  41. Georgii A, Buesche G, Kreft A . The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998; 11: 721–749.

    Article  CAS  PubMed  Google Scholar 

  42. Thiele J, Kvasnicka HM, Muehlhausen K, Walter S, Zankovich R, Diehl V . Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. Pathol Res Pract 2001; 197: 77–84.

    Article  CAS  PubMed  Google Scholar 

  43. Thiele J, Kvasnicka HM, Diehl V . Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005; 20: 633–644.

    CAS  PubMed  Google Scholar 

  44. Thiele J, Kvasnicka HM . The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009; 4: 33–401.

    Article  PubMed  Google Scholar 

  45. Buhr T, Georgii A, Choritz H . Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993; 189: 121–132.

    Article  CAS  PubMed  Google Scholar 

  46. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012; 119: 2239–2241.

    Article  CAS  PubMed  Google Scholar 

  47. Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van Der Walt J, Orazi A . European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128–1132.

    PubMed  Google Scholar 

  48. McMullin MF . The classification and diagnosis of erythrocytosis. Int J Lab Hem 2008; 30: 447–459.

    CAS  Google Scholar 

  49. Kvasnicka HM, Thiele J . Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85: 62–66.

    PubMed  Google Scholar 

  50. Pierre R, Imbert M, Thiele J, Vardiman J, Brunning R, Flandrin G . Polycythemia vera. In: Jaffe ES, Harris HL, Stein H, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001; pp 32–34.

    Google Scholar 

  51. Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.

    Article  CAS  PubMed  Google Scholar 

  52. Tefferi A . Diagnosing polycythemia vera: a paradigma shift. Mayo Clin Proc 1999; 74: 159–162.

    Article  CAS  PubMed  Google Scholar 

  53. Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004; 89: 1194–1198.

    CAS  PubMed  Google Scholar 

  54. Lemoine F, Najman A, Baillou C, Stachowiak J, Boffa G, Aegerter P et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood 1986; 68: 996–1002.

    CAS  PubMed  Google Scholar 

  55. Weinberg RS, Worsley A, Gilbert HS, Cuttner J, Berk PD, Alter BP . Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies. Leuk Res 1989; 13: 331–338.

    Article  CAS  PubMed  Google Scholar 

  56. Juvonen E, Ikkala E, Oksanen K, Ruutu T . Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993; 83: 192–197.

    Article  CAS  PubMed  Google Scholar 

  57. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656–664.

    Article  Google Scholar 

  58. Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E et al. Masked Polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2013; e-pub ahead of print 26 October 2013; doi:10.1002/ajh.23617.

    Article  CAS  PubMed  Google Scholar 

  59. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368: 22–33.

    Article  CAS  PubMed  Google Scholar 

  60. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 2013; 121: 4778–4781.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Tefferi A . Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 285–293.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

TB and AMV were supported by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC, Milano) ‘Special Program Molecular Clinical Oncology 5 × 1000’ to AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative).

Author information

Authors and Affiliations

  1. Papa Giovanni XXIII Hospital, Research Foundation, Bergamo, Italy

    T Barbui

  2. Institute of Pathology, University of Cologne, Cologne, Germany

    J Thiele

  3. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

    A M Vannucchi

  4. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    A Tefferi

Authors
  1. T Barbui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Thiele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A M Vannucchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Tefferi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Barbui.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barbui, T., Thiele, J., Vannucchi, A. et al. Rethinking the diagnostic criteria of polycythemia vera. Leukemia 28, 1191–1195 (2014). https://doi.org/10.1038/leu.2013.380

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.380

Keywords

This article is cited by

Search

Advanced search

Quick links